INTRODUCTION
Alternating hemiplegia of childhood (AHC) is a rare, early onset neurodevelopmental disorder with a prevalence of 1:100,000 [Hoei-Hansen et al., 2014] characterized by paroxysmal manifestations of tonic, dystonic, and/or hemiplegic attacks, and oculomotor abnormalities. All these manifestations can be triggered by factors such as psychological or physical stress. Typically, these phenomena regress with transition from wakefulness to sleep. Epileptic seizures with a variable pattern have also been reported [Neville and Ninan, 2007] . Additional non-paroxysmal signs such as marked hypotonia, dystonia, tremor, ataxia, and intellectual disability (ID) of variable degree are also present.
Alternating hemiplegia of childhood usually manifests within 18 months of age, but in a large group of patients the first clinical signs occur even earlier, usually before 6 months [Panagiotakaki et al., 2015] .
The classic neurologic diagnostic criteria include: (i) onset before 18 months of age; (ii) paroxysmal occurrence of tonic/dystonic spells, oculomotor alterations, and autonomic phenomena; (iii) repeated attacks of hemiplegia involving either side of the body; (iv) recovery from attacks upon sleeping; and (v) ID of variable degree [Bourgeois et al., 1993] .
The course of the disease is variable ranging from mild psychomotor impairment to severe disability from early childhood. Sudden death has also been reported in a few patients.
In 2012, mutations in ATP1A3 were identified as causative for AHC [Heinzen et al., 2012] . At that time, it was already known that another condition, rapid-onset dystonia-parkinsonism (RDP) was caused by alterations in the same gene, but at different sites. Another neurological phenotype, cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS)
Festschrift honoring John C. Careysyndrome, was subsequently found to be caused by different mutations in this same gene [Sweney et al., 2015] . Rapid-onset dystonia-parkinsonism is characterized by acute or subacute onset of rapidly evolving dystonia and parkinsonism in adolescence or adulthood (variably between 9 months and 59 years) after a physical or psychological trigger. The CAPOS syndrome [Nicolaides et al., 1996] manifests with early onset cerebellar ataxia, areflexia, pes cavus deformity, optic atrophy, and sensorineural hearing loss. Usually, an abrupt onset of neurological symptoms occurs, predominantly hypotonia and ataxia, triggered by stressors such as a fever, with onset from 9 to 16 months.
Whereas RDP is usually dominantly inherited, CAPOS syndrome and AHC appear sporadically, being due to de novo mutations in ATP1A3.
Mutations in the coding region of ATP1A3 are detected in 75-90% of patients with a clinical diagnosis of AHC, indicating that additional causative genes, yet unknown, might exist. ATP1A3 encodes the sodium-potassium (Naþ/Kþ) ATPase alpha three subunit, whose assembly with other subunits results in a pump that plays a critical role in maintaining the electrochemical gradients of Naþ and Kþ across the plasma membrane: upon ATP hydrolysis, three Naþ ions are exchanged with two Kþ ions. Altogether there are four alpha subunits (1-4) and three of them (1-3) are expressed in the nervous system [McGrail et al., 1991] . After the discovery that AHC and RDP are allelic conditions, it has been observed that the mutational spectrum of these two conditions is distinct, suggesting that AHC-associated mutations have a more severe functional and clinical impact as compared to those associated with RDP. Exceptionally, a typical RDP mutation has been reported in one AHC patient [Boelman et al., 2014] . In both conditions, the biological mechanisms underlying stress intolerance in neurons with ATP1A3 alterations are still unknown.
Although more than 30 ATP1A3 mutations have been reported in patients with AHC, it is clear that a mutational clustering does exist, as more than 50% of patients have either one of two recurrent mutations, that is, p.Asp801Asn (c.2401G>A) or p.Glu815Lys (c.2443G>A). A third mutation, the p.Gly947Arg (c.2839G>A or c.2839G>C), is also quite frequent in Caucasian patients with AHC. The p.Glu815Lys mutation is clearly associated with the most severe neurological phenotype.
Whereas the neurological profile of patients with AHC has been extensively delineated, the question whether a recognizable pattern of physical anomalies exists in this condition is still open. In an attempt to identify a recognizable physical profile for AHC, we performed a morphological evaluation at different ages of 30 patients with a neurological diagnosis of AHC. The purpose of this report is to draw attention to some physical signs, common to AHC patients, detectable at different ages, but especially in early childhood, and to show the changes of this phenotype with age. The result of this analysis is the delineation of a typical physical phenotype that is recognizable upon morphological examination of the patient.
METHODS
Each patient underwent a thorough morphological evaluation and photographs were taken upon written consent by parents. Parents also kindly provided photographs taken in early childhood.
Pre-and post-natal history was recorded. The study has been approved by the ethical board of the Italian Association for AHC (AISEA).
Three of the four authors (FG, FDT, and GN) evaluated each patient in person separately and reached a consensus. However, we determined that our conclusions be validated by an independent expert. Therefore, we submitted clinical reports and photographs to GZ who suggested that the description of the early age phenotype be separated from that seen at an older age. Indeed, the phenotype observed in early childhood bears significant differences with respect to that manifesting at an adult age. A final consensus was reached whose result is summarized in Tables I and II. All patients were tested by Sanger sequencing of the coding region of ATP1A3 and were previously reported [Heinzen et al., 2012] : the mutation synopsis is reported in the Tables. Four out of 30 (13%) individuals did not have identified mutations, but the diagnosis of AHC could be supported on the basis of the neurological manifestations. However, their physical descriptions were not included in this report. Figure 1 is a compilation of the facial phenotypes in early infancy. Figure 2 reports the facial phenotype in childhood and Figure 3 , the facial appearance in adulthood. For some patients, images at two different ages were available. Some patients were examined only in adult life.
RESULTS

Pre-and Peri-Natal Findings
Information on possible peri-conceptional exposures and on pregnancy were recorded in 24/30 patients. A total of 9/30 fathers were working in industries with a potential risk of exposure to genotoxic agents (such as polyurethane, tin, and xylol) in the peri-conceptional period. One third of these pregnancies was characterized by reduced fetal movements, fetal hiccups but normal fetal growth.
Half of the births were by caesarean delivery and marked hypotonia was recorded in all patients. Neurological issues, including abnormal eye movements, seizures, or paroxysmal episodes occurred between the first few days and 18 months.
By evaluating the pictures taken in early infancy a few findings appeared to be present in all patients ( Fig. 1) : a wide, prominent forehead, thin but well-defined eyebrows extending to the temporal side of the forehead, depressed nasal bridge, long philtrum, drooping cheeks, downturned corners of mouth, enhanced cupid's bow of the upper lip with everted lower lip vermilion (Table I) .
As shown in Figure 2 , the facial appearance became more striking with age. In most patients, the frontal bossing disappeared, but the eyebrows were even more typical in 20 out of 26 patients. With the persistence of hypotonia, the palpebral fissures may become down slanting with a full periorbital region. The philtrum appeared long, while the mouth was large and almost maintained the appearance observed in early infancy.
The degree of ID correlated with the type of ATP1A3 alteration, being most severe in patients with p.Glu815Lys or slightly less in those with the p.Asp801Asn mutation. Motor impairment was a common finding and, especially in adult life, some patients had difficulties in ambulation, and a few were wheelchair-bound. The p.Ala955Asp (c.2864C>A) and p.Leu888Pro (c.2663T>C) mutations (patients 17 and 2, respectively) were also associated with a severe clinical presentation: patient 17 had severe epileptic encephalopathy, no self care skills, absence of expressive language, and episodes of hyperventilationThe patients who had alterations of milder effect, such as the p.Gly947Arg, p.Met806Arg (c.2417T>G) or p.Ala338Pro (c.1012G>C), appeared to have cognitive and motor disability, but developed expressive language, and motor skills. Patient 5, with the p.Val919del (c.2755_2757delGTC) mutation, unique among all those reported so far, had apparent ID, and was able to author a book entitled "The Convoy of Trucks." However, it should be noted that also patient 4, who had the similarly severe mutation p.Asp801Asn, was still able to author an autobiographical book entitled "Andrea's Wonderful World." With the exception of patients with severe neurodevelopmental impairment, we noticed a strong attitude toward socialization. Patient 24, when informed that he was a carrier of the p.Gly947Arg mutation, told us that he felt happy about this discovery, not for himself, as he was already over 40, but for the younger patients who could benefit from a targeted therapy.
DISCUSSION
Several conditions with epilepsy, encephalopathy, and developmental delay share clinical manifestations with AHC: among those, Angelman and Pitt-Hopkins syndromes [Margolis et al., 2015] . One patient of this cohort, patient 17, underwent molecular testing for TCF4, because he also had episodes of hyperventilation; only when a hemiplegic attack was recorded did he receive a diagnosis of AHC, confirmed by mutational analysis of ATP1A3. He also had molecular testing for Angelman syndrome as did many other patients in the study. Clearly, the phenotypic overlap between these conditions is limited to the clinical presentation of the most severe ATP1A3 mutations, such as p.Glu815Lys and p.Ala955Asp. With respect to Angelman syndrome, it should be noted that the typical prominent mandibular bone is not present in patients with AHC, who also lack the inappropriate laughing episodes and the typical EEG pattern. Also, even in those patients with the p.Glu815Lys variant, it is possible to observe some language development. The occurrence of hyperventilation episodes among other autonomic dysfunctions may lead to suspect a diagnosis of Pitt-Hopkins syndrome, again in patients with severe AHC. Aside from the different gestaltic appearance, the neurological involvement in AHC is characterized by more specific manifestations (recurrent hemiplegic attacks and dystonia) than in Pitt-Hopkins syndrome. Furthermore, there are usually no brain alterations or microcephaly in patients with AHC whereas these findings can be present in those with Pitt-Hopkins syndrome [Tan et al., 2014] . Other severe early onset epileptic encephalopathies in need of differential diagnosis include Dravet and Ohtahara syndromes [Nakamura et al., 2013] , caused by alterations in SCN1A or SCN2A, respectively. In these conditions, the differential diagnosis can be difficult. However, the untractable epilepsy is more typical of SCN2A mutations. Obviously, the occurrence of episodic hemiplegia, which can be difficult to observe, clearly distinguishes AHC from all these conditions. The clinical picture caused by milder ATP1A3 alterations may overlap with that of hemiplegic migraine and other channelopathies. Usually, in the case of hemiplegic migraine, the family history is positive, and no developmental disabilities or seizures are evident.
Although AHC is usually considered a purely neurodevelopmental condition, we found that almost 22 of 26 patients with a confirmed molecular alteration in ATP1A3 shared a similar physical phenotype consisting of generalized hypotonia, long face, thin and well-defined eyebrows, strabismus, widely spaced eyes, long palpebral fissures, downturned mouth, and slender habitus. We consider this phenotype sufficiently typical to delineate a recognizable gestalt. These physical findings, together with the neurological manifestations, even in the absence of the typical episodic hemiplegia, should prompt the diagnostic suspicion of AHC and induce the genetic testing. To ensure full diagnostic coverage for AHC, it is advisable to include ATP1A3 in genetic testing panels including other genes responsible for epileptic encephalopathies.
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